tirzepatide and diabetes How Does Work? Peptide of the Week: Tirzepatide,

| 05.04.26 | 10 min read

The researchers, including from the University of Pennsylvania in the US, wrote in the British Medical Journal (BMJ): Case reports and analyses of the US Food and Drug Administration (FDA)s Adverse Event Reporting System have described occurrences of hair loss following initiation of a GLP-1 receptor agonist, particularly semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro)

Animal studies have shown risks like pregnancy loss and developmental issues

A few rules that apply across all use cases: Consistency matters more than dose size

The free assessment quiz captures GI history including IBS, prior bowel surgery, and current medications that affect transit (opioids, anticholinergics)

Safe & Effective Formula: Gentle on the stomach and free from gluten, parabens, and harmful chemicals